About
IASO Bio develops cell therapies and biologics for hematologic malignancies and autoimmune diseases. It operates in Nanjing, Shanghai, and Pleasanton, with global R&D, clinical, and manufacturing activities spanning discovery through commercialization.
Services
Fully Human Antibody Discovery Platform
Uses a fully human antibody library of over 240 billion antibodies, plus synthetic and single-domain libraries, to support discovery of antibody candidates and next-generation therapies.
High-throughput CAR-T Cell Therapy Screening and Optimization Platform
Uses single-cell analysis and next-generation sequencing to screen and optimize CAR-T lead candidates based on phenotypic and functional metrics.
In Vivo CAR-T Platform
Develops in vivo CAR-T products using viral vector engineering, T cell-specific promoters, and proprietary envelope modifications to improve selective T cell transduction and safety.
Advanced Manufacturing and CMC Platform
Provides end-to-end manufacturing and quality systems to support development and commercial-scale production of cell and gene therapy products.
Plasmid Manufacturing
Produces research, GMP-grade, and injectable-grade plasmids using fermentation, purification, in-process analytics, sterilization, and Class A filling.
Lentiviral Vector Manufacturing
Produces lentiviral vectors in a closed, automated, scalable system with batch release testing for identity, potency, sterility, residual DNA, and host-cell protein.
Cell Process Development and Manufacturing
Develops cell products for GMP-compliant manufacturing and supports GMP grade plasmids, viral vectors, and cells.
Clinical Development and Clinical Translational Research Platform
Operates a joint laboratory with a top-tier Chinese hospital to integrate research and clinical development.
1 more services
- Cell product process development and GMP manufacturing
- What to send
- Single intravenous infusion of IASO208
- Patients are not required to undergo conventional apheresis or lymphodepleting conditioning
Capabilities
- Assays and studies
- Cell therapy
- In vivo
- Antibodies
- Lentivirus
- NGS
- Flow cytometry
12 more
- Process development
- Single-cell analysis
- Next-generation sequencing
- Molecular detection
- Cell function assays
- Identity testing
- Potency testing
- Sterility testing
- Residual DNA testing
- Host-cell protein assays
- Cell function testing
- Host-cell protein testing
- Scale and capacity
- Over 240 billion antibodies
- Nanjing Facility: approximately 7,866 square meters GFA
- Shanghai Facility: 32,306 square meters GFA
- Four global R&D and manufacturing sites
- Fully integrated platforms spanning the entire product lifecycle
- Over 240 billion antibodies in the fully human antibody library
3 more
- Ten products and product candidates
- Nanjing facility: approximately 7,866 square meters
- Shanghai facility: 32,306 square meters
- Therapeutic areas
- Hematological malignancies
- Autoimmune diseases
- Multiple myeloma
- Relapsed/refractory B-cell non-Hodgkin lymphoma
- B-cell malignancies
- Myasthenia gravis
4 more
- Multiple sclerosis
- Systemic lupus erythematosus
- Lupus nephritis
- B-cell non-Hodgkin lymphoma
Modalities and species
- Modalities
- Antibody
- Bispecific
- mRNA
- Viral vector
- Cell therapy
- Gene editing
- Plasmid DNA
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: cell product process development
Industries served
- Advanced therapy medicinal products
- Cell therapy
- Gene therapy
Company
- Type
- CRDMO
- Founded
- 2017
Locations
- Address
- 1 Xinjinhu Road, Jiangbei New District, Nanjing, Jiangsu Province 210018
- Sites
- Shanghai, China
- Pleasanton, United States
- Pleasanton, CA, United States
- Serves
- China, United States, Singapore, Saudi Arabia, United Arab Emirates, Hong Kong, Japan, Australia, Korea
Contacts
- Phone
- +86 025-58287610